Login to Your Account



Earnings Roundup


Friday, February 24, 2012
• Dyax Corp., of Burlington, Mass., reported in its fourth-quarter earnings that net sales of hereditary angioedema drug Kalbitor (ecallantide) increased to $7 million, a 130 percent jump over the fourth quarter of 2010. For the year, Kalbitor sales increased 160 percent to $22.9 million, contributing to the firm's 2011 revenues of $48.7 million. Revenue for the fourth quarter totaled $8.5 million, and the net loss was $13.5 million, or 14 cents per share, marking a slightly wider loss than the 10 cents per share predicted by analysts.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription